Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine is an experimental small molecule compound belonging to the class of phenylpyridines and organoheterocyclic compounds. It has a molecular formula of C18H14BrN5 and a molecular weight of approximately 380.24 g/mol. The compound is not approved for clinical use in any region and has no known indications or associated conditions in clinical trials. According to DrugBank, it may interact with cyclin-dependent kinase 2 (CDK2), suggesting potential activity as a kinase inhibitor; however, there are no published data on its mechanism of action or therapeutic applications in humans.[1][2][3][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine.